Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of myocardial infarction (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of suspected serious drug reactions (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Donor site healing time in days for adults · adults with skin graft donor sites
It is very uncertain whether summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel… changes time to complete wound healing of skin graft donor sites (days)… compared with OCT‐free placebo hydrogel dressings (very low certainty).
1 finding from 1 review
Donor site pain · adults with skin graft donor sites
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · adults with skin graft donor sites
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Wound infection (bacterial colonisation) Measured using: contact cultures · adults with skin graft donor sites
1 finding from 1 review
Wound complications · adults with skin graft donor sites
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with skin graft donor sites
It is very uncertain whether summary of findings 2. Octenidine‐dihydrochloride (OCT) hydrogel… changes adverse events compared with OCT‐free placebo hydrogel dressings (very low certainty).
1 finding from 1 review
Outcomes (measurement) · asymptomatic carotid stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neurological impairment · asymptomatic carotid stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ipsilateral major or disabling stroke · asymptomatic carotid stenosis
Antihypertensive agent showed no clear difference in ipsilateral major or disabling stroke (not reported) compared with placebo (low certainty).
1 finding from 1 review
Stroke‐related mortality · asymptomatic carotid stenosis
Antihypertensive agent showed no clear difference in stroke‐related mortality (not reported) compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · asymptomatic carotid stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression of carotid stenosis · asymptomatic carotid stenosis
Antihypertensive agent may leads to lower progression of carotid stenosis (DUS/at beginning and end) compared with placebo (low certainty).
1 finding from 1 review
Adverse events · asymptomatic carotid stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found